BHVN$10.01
$10.29
Chart
Performance
Key Stats
AI BHVN Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralBiohaven Ltd. shows potential in its long-term growth outlook, but its current financial performance and recent price action indicate a need for caution. Further research into its product pipeline and clinical trial outcomes is recommended.
Thematic
Biohaven Ltd. is focused on developing therapies for immunology, neuroscience, and oncology, which are significant and growing markets. However, the success of its diverse pipeline is uncertain and dependent on clinical trial outcomes.
Fundamental
Biohaven Ltd. is currently unprofitable with no revenue reported, relying on its cash reserves and financing activities. Its balance sheet shows substantial assets but also increasing liabilities and negative free cash flow.
Technical
The stock has experienced a significant decline, trading well below its 52-week high. Technical indicators suggest strong selling pressure and a bearish trend, with multiple moving averages indicating a sell signal.
| Factor | Score |
|---|---|
| Neuroscience and Immunology Focus | 80 |
| Oncology Development | 70 |
| Biotechnology Sector Trends | 65 |
| Partnerships and Collaborations | 70 |
| Regulatory Landscape | 50 |
| Factor | Score |
|---|---|
| Valuation | 20 |
| Profitability | 10 |
| Growth | 10 |
| Balance Sheet Health | 70 |
| Cash Flow | 25 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 40 |
| Volume Confirmation | 45 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (4)
Adequate Cash Reserves
The company ended the latest quarter with $102.54 million in cash and cash equivalents, providing a buffer for operational needs.
Momentum Indicators Suggest Buying
Several short-term technical indicators, including Stochastic %K, Commodity Channel Index, and Williams Percent Range, are showing 'Buy' signals, suggesting potential upward momentum.
Bearish Points (8)
Negative Earnings Per Share (EPS)
The reported EPS for Q4 2024 was -$1.70, and for the trailing twelve months (TTM) was -$9.25, indicating consistent unprofitability.
No Revenue Reported
The provided data shows zero revenue for all reported periods (TTM, 2024, 2023, 2022, 2021), which is a significant concern for business viability.
Calendar
August 2025
12
Next Earnings Date
H: $-1.17
A: $-1.57
L: $-2.32
Profile
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Seasonals
Price Target
54.21 USD
The 39 analysts offering 1 year price forecasts for BHVN have a max estimate of 75.00 and a min estimate of 21.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Acquired Biohaven's flagship migraine drug, Nurtec ODT, in 2022, creating a direct and significant historical link.
Weight: 95
Major competitor in the oral CGRP migraine market with Ubrelvy and Qulipta, directly competing with Biohaven's former primary asset.
Weight: 90
A key competitor in the CGRP migraine market with Emgality and possesses a strong and active neuroscience pipeline, overlapping with Biohaven's therapeutic areas.
Weight: 88
Offers Aimovig, another leading CGRP inhibitor for migraine prevention, making it a direct competitor in Biohaven's past core market.